Patents by Inventor Anders Vahlne

Anders Vahlne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGH AFFINITY ADAPTOR MOLECULES FOR REDIRECTING ANTIBODY SPECIFITY
    Publication number: 20160251400
    Abstract: Disclosed are methods for identifying high affinity adaptor molecules that bind to both a circulating antibody and a target molecule and redirect the specificity of the circulating antibody to the target molecule. Exemplary high affinity adaptor molecules are also provided.
    Type: Application
    Filed: February 2, 2016
    Publication date: September 1, 2016
    Inventors: Albert Collinson, Peter Wagner, Matti Sallberg, Anders Vahlne, Gregor Schurmann, Robert Kamen
  • High affinity adaptor molecules for redirecting antibody specifity
    Patent number: 9284548
    Abstract: Disclosed are methods for identifying high affinity adaptor molecules that bind to both a circulating antibody and a target molecule and redirect the specificity of the circulating antibody to the target molecule. Exemplary high affinity adaptor molecules are also provided.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: March 15, 2016
    Assignee: Tripep AB
    Inventors: Albert Collinson, Peter Wagner, Matti Sällberg, Anders Vahlne, Gregor Schürmann, Robert Kamen
  • Glycosylated specificity exchangers
    Patent number: 9079962
    Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: July 14, 2015
    Assignee: TRIPEP AB
    Inventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
  • GLYCOSYLATED SPECIFICITY EXCHANGERS
    Publication number: 20140081004
    Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
    Type: Application
    Filed: November 20, 2013
    Publication date: March 20, 2014
    Inventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
  • Glycosylated specificity exchangers
    Patent number: 8658179
    Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: February 25, 2014
    Assignee: Chrontech Pharma AB
    Inventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
  • Glycosylated specificity exchangers
    Patent number: 8303956
    Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: November 6, 2012
    Assignee: Chrontech Pharma AB
    Inventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
  • HIGH AFFINITY ADAPTOR MOLECULES FOR REDIRECTING ANTIBODY SPECIFITY
    Publication number: 20120271033
    Abstract: Disclosed are methods for identifying high affinity adaptor molecules that bind to both a circulating antibody and a target molecule and redirect the specificity of the circulating antibody to the target molecule. Exemplary high affinity adaptor molecules are also provided.
    Type: Application
    Filed: October 5, 2010
    Publication date: October 25, 2012
    Applicant: OPSONIC THERAPEUTICS INC.
    Inventors: Albert Collinson, Peter Wagner, Matti Sällberg, Anders Vahlne, Gregor Schürmann, Robert Kamen
  • GLYCOSYLATED SPECIFICITY EXCHANGERS
    Publication number: 20100183635
    Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
    Type: Application
    Filed: March 26, 2010
    Publication date: July 22, 2010
    Applicant: TRIPEP AB
    Inventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
  • INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS
    Publication number: 20090170953
    Abstract: The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HIV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.
    Type: Application
    Filed: October 30, 2007
    Publication date: July 2, 2009
    Applicant: Tripep AB
    Inventors: Jan Maria Balzarini, Anders Vahlne, Marita Hogberg, Weimin Tong
  • Glycosylated specificity exchangers
    Patent number: 7534435
    Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
    Type: Grant
    Filed: April 26, 2006
    Date of Patent: May 19, 2009
    Assignee: Tripep AB
    Inventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
  • GLYCOSYLATED SPECIFICITY EXCHANGERS THAT INDUCE AN ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) RESPONSE
    Publication number: 20090092631
    Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
    Type: Application
    Filed: March 25, 2008
    Publication date: April 9, 2009
    Applicant: TRIPEP AB
    Inventors: Matti Sallberg, Anders Vahlne, Maria Perdomo
  • Compounds That Inhibit Replication Of Human Immunodeficiency Virus
    Publication number: 20080076824
    Abstract: The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HUV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.
    Type: Application
    Filed: August 16, 2005
    Publication date: March 27, 2008
    Inventors: Jan Balzarini, Anders Vahlne, Marita Hogberg, Weimin Tong
  • Glycosylated specificity exchangers
    Patent number: 7335359
    Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: February 26, 2008
    Assignee: Tripep AB
    Inventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
  • Glycosylated specificity exchangers
    Patent number: 7332166
    Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
    Type: Grant
    Filed: April 26, 2006
    Date of Patent: February 19, 2008
    Assignee: Tripep AB
    Inventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
  • Molecules that block viral infectivity and methods of use thereof
    Publication number: 20070037249
    Abstract: Embodiments relate to the discovery that certain tripeptide amides and glycine amide can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said tripeptide amides and/or glycine amide and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.
    Type: Application
    Filed: January 6, 2006
    Publication date: February 15, 2007
    Inventors: Laura Goobar-Larsson, Anders Vahlne
  • Identification of compounds that inhibit replication of human immunodeficiency virus
    Publication number: 20060188920
    Abstract: The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HIV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.
    Type: Application
    Filed: April 24, 2006
    Publication date: August 24, 2006
    Inventors: Jan Maria Balzarini, Anders Vahlne, Marita Hogberg, Weimin Tong
  • Identification of compounds that inhibit replication of human immunodeficiency virus
    Publication number: 20060183748
    Abstract: The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HIV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.
    Type: Application
    Filed: April 25, 2006
    Publication date: August 17, 2006
    Inventors: Jan Maria Balzarini, Anders Vahlne, Marita Hogberg, Weimin Tong
  • Antiviral composition comprising glycine amide
    Patent number: 7012129
    Abstract: Embodiments relate to the discovery that certain tripeptide amides and glycine amide can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said tripeptide amides and/or glycine amide and methods of using said compounds for the prevention and treatment of viral infection, such as HIV infection, are provided.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: March 14, 2006
    Assignee: Tripep AB
    Inventors: Anders Vahlne, Laura Goobar-Larsson
  • Identification of compounds that inhibit replication of human immunodeficiency virus
    Publication number: 20050096319
    Abstract: The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HIV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.
    Type: Application
    Filed: August 18, 2004
    Publication date: May 5, 2005
    Inventors: Jan Balzarini, Anders Vahlne, Marita Hogberg, Weimin Tong
  • Identification of compounds that inhibit replication of human immunodeficiency virus
    Publication number: 20040180893
    Abstract: The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HIV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.
    Type: Application
    Filed: February 19, 2004
    Publication date: September 16, 2004
    Inventors: Jan Maria Rene Balzarini, Anders Vahlne, Marita Hogberg, Weimin Tong